Lin Shao-Lee's Form 4/A amendment
AmendedCue Biopharma, Inc. (CUE) · filed Jul 30, 2026
- Accession no.
- 0001725092-26-000009
- Filed
- Jul 30, 2026, 4:35 PM ET
- Trade date
- Jun 1, 2026
- Filing delay
- 59 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Jun 1, 2026
This filing lists 0 non-derivative transactions and 2 derivative transactions. It was filed 59 days after the trade.
This amendment replaces 0001725092-26-000004 (filed Jun 3, 2026).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lin Shao-LeeCIK 0001725092 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Common Stock | AGrant or awardAcquired | +90,906 | $11.00 | +$999,966 | 90,906 | Indirect | |
| Jun 1, 2026 | Common Stock | AGrant or awardAcquired | +45,453 | – | – | 45,453 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.